InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | 2026-03-23 | Jaumot Frank E | Director | Purchase | 150 | $93.56 | $14K | 150 | View ↗ | |
| 2026-03-19 | 2026-03-23 | Hosseinion Warren | Director & President | Purchase | 252 | $94.07 | $24K | 7,765 | View ↗ | |
| 2026-03-17 | 2026-03-18 | Spears Kelvin | Director | Purchase | 10 | $94.46 | $944.60 | 32.1K | View ↗ | |
| 2026-03-13 | 2026-03-16 | Montgomery Pamela W. | Chief Legal Officer-Healthcare | Purchase | 79 | $88.87 | $7K | 2,758 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $31.1M+0.7% | $30.9M+4.4% | $29.6M+42.3% | $20.8M-93.7% | $331.5M |
| Payroll | $158.1M+34.5% | $117.5M+8.4% | $108.4M-3.0% | $111.8M+19.5% | $93.5M |
| Contract services | $190.3M+88.9% | $100.8M+137.9% | $42.4M+17.9% | $35.9M+110.6% | $17.1M |
| Medical supplies | $17.2M+12.8% | $15.3M+8.0% | $14.2M+16.8% | $12.1M-3.2% | $12.5M |
| Depreciation and amortization | $20.5M+8.2% | $19.0M+7.8% | $17.6M+34.0% | $13.1M+71.4% | $7.7M |
| Other | $44.8M+43.9% | $31.1M+2.5% | $30.4M-1.7% | $30.9M+43.8% | $21.5M |
| Total operating costs and expenses | $431.0M+51.9% | $283.7M+33.3% | $212.9M+4.4% | $203.9M+33.9% | $152.3M |
| Gross profit | $444.3M+126.4% | $196.3M+464.4% | $34.8M+125.5% | $15.4M-91.4% | $179.3M |
| Facilities closing costs | $0 | $0-100.0% | $217K | — | — |
| Acquisition costs | $0 | $0-100.0% | $44K-98.9% | $3.9M+9.3% | $3.6M |
| Stock-based compensation | $117.0M+606.8% | $16.6M+483.7% | $2.8M+1395.9% | $190K | — |
| Impairment of assets | $0-100.0% | $3.9M-86.6% | $29.1M | — | — |
| Impairment of goodwill | $0-100.0% | $3.2M+180.7% | $1.1M-99.7% | $398.1M | — |
| General and administrative expenses | $51.7M+23.2% | $41.9M+26.2% | $33.2M+67.7% | $19.8M+262.7% | $5.5M |
| Total corporate and other costs | $168.7M+157.2% | $65.6M-1.5% | $66.5M-84.2% | $422.0M+4580.8% | $9.0M |
| Operating income (loss) | $275.6M+110.9% | $130.7M+511.3% | -$31.8M+92.2% | -$406.6M-338.8% | $170.3M |
| Interest expense, net | $22.2M+11.5% | $19.9M+22.1% | $16.3M+30.6% | $12.5M+101.6% | $6.2M |
| Loss on warrant liability | $0-100.0% | $1.6M | $0 | — | — |
| Other (income) expense | $8.6M+1388.2% | -$669K-267.7% | $399K-28.7% | $559K+110.3% | -$5.4M |
| Income (loss) before taxes | $244.8M+122.9% | $109.8M+326.5% | -$48.5M+88.4% | -$419.6M-347.6% | $169.5M |
| Income tax expense (benefit) | $64.4M+328.9% | $15.0M+396.4% | -$5.1M-138.7% | $13.1M+1255.5% | $966K |
| Net income (loss) | $180.4M+90.2% | $94.8M+318.3% | -$43.4M+90.0% | -$432.7M-356.8% | $168.5M |
| Less: net income attributable to noncontrolling interests | $109.6M+156.5% | $42.7M+1707.4% | $2.4M+129.7% | -$8.0M-122.2% | $35.9M |
| Net income (loss) attributable to Nutex Health Inc. | $70.8M+35.9% | $52.1M+213.8% | -$45.8M+89.2% | -$424.8M-420.4% | $132.6M |
| Basic earnings (loss) per common share (in dollars per share) | $11.13+8.8% | $10.23+198.5% | -$10.39-1450.7% | -$0.67-404.5% | $0.22 |
| Diluted earnings (loss) per common share (in dollars per share) | $10.48+8.2% | $9.69+193.3% | -$10.39-1450.7% | -$0.67-404.5% | $0.22 |
| Hospital division | |||||
| Population health management division | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Nutex Health NUTX Q2 2025 Earnings Transcript
Explore These 3 Undervalued Small Caps With Insider Buying Across Regions
Nutex Health And 2 Other Undiscovered Gems In The US Market
A Look At Nutex Health (NUTX) Valuation After Strong Q1 2026 Results And New Buyback Program